Amgen lightens the mood in a new TV ad for cholesterol med Repatha even as Amgen continues a patent dispute and price drops for the drug.

Roche’s Tecentriq scored some big wins lately, including a pair of first-in-class approvals. But in other cancers, it's decided to pull the plug.

Allergan’s digital booking platform for aesthetic treatments helps consumers find Allergan-branded medical aesthetics but also regular spa services.

Gilead Sciences launched its first national TV campaign for HIV treatment Biktarvy featuring a broad range of different people living with HIV.

Evenity's annual price of $21,900 is on par with that of Radius' rival med Tymlos. But its safety and clinical efficacy profile might hurt uptake.

Look out, Roche and Regeneron. Thanks to an FDA priority review, Novartis eye candidate brolucizumab could start stealing sales in October.

Pharmaceutical ad spending continued its upward climb last year, with spending topping $6.46 billion, according to Kantar Media.

Clovis Oncology's PARP inhibitor Rubraca didn't spur enough response to warrant continuing a phase 2 bladder cancer study.